Vifor Pharma AG
Vifor Pharma AG Fundamental Analysis
Vifor Pharma AG (VIFN.SW) shows weak financial fundamentals with a PE ratio of 40.61, profit margin of 14.55%, and ROE of 7.52%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 66.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze VIFN.SW's fundamental strength across five key dimensions:
Efficiency Score
WeakVIFN.SW struggles to generate sufficient returns from assets.
Valuation Score
ModerateVIFN.SW shows balanced valuation metrics.
Growth Score
WeakVIFN.SW faces weak or negative growth trends.
Financial Health Score
ExcellentVIFN.SW maintains a strong and stable balance sheet.
Profitability Score
WeakVIFN.SW struggles to sustain strong margins.
Key Financial Metrics
Is VIFN.SW Expensive or Cheap?
P/E Ratio
VIFN.SW trades at 40.61 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, VIFN.SW's PEG of 0.41 indicates potential undervaluation.
Price to Book
The market values Vifor Pharma AG at 3.09 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 0.63 times EBITDA. This is generally considered low.
How Well Does VIFN.SW Make Money?
Net Profit Margin
For every $100 in sales, Vifor Pharma AG keeps $14.55 as profit after all expenses.
Operating Margin
Core operations generate 10.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.52 in profit for every $100 of shareholder equity.
ROA
Vifor Pharma AG generates $5.20 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $4.76 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
40.61
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.41
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.09
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.17
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.91
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How VIFN.SW Stacks Against Its Sector Peers
| Metric | VIFN.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 40.61 | 28.48 | Worse (Expensive) |
| ROE | 7.52% | 777.00% | Weak |
| Net Margin | 14.55% | -20226.00% (disorted) | Strong |
| Debt/Equity | 0.17 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 1.91 | 4.66 | Neutral |
| ROA | 5.20% | -14638.00% (disorted) | Weak |
VIFN.SW outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Vifor Pharma AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation